Targets › CD79B
5 programs from 5 companies in 49 trials: 32 Phase 2, 12 Phase 1, 4 Phase 3, 1 Phase 4; Oncology; next expected readout Feb 2027.
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. (UniProt, P40259)
Open in Phaseline: the race on CD79B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Polatuzumab vedotin B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor | CD79B, Tubulin | Phase 3 | Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma … | Feb 2027 |
| Memorial Sloan Kettering Cancer Center | Polatuzumab Anti-CD79B antibody-drug conjugate | CD79B | Phase 2 | Diffuse Large B Cell Lymphoma (DLBCL) | Jan 2028 |
| Beijing Tongren Hospital | Polatuzumab Anti-CD79B antibody-drug conjugate | CD79B | Phase 2 | Diffuse Large B Cell Lymphoma (DLBCL) | Feb 2028 |
| Johnson & Johnson (Janssen) | JNJ-80948543 T-cell redirecting trispecific antibody against CD79b, CD20, and CD3 | CD79B, CD20, CD3 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| Marcela V. Maus, M.D.,Ph.D. | CD79b-19 CAR T cells CAR-T cells targeting CD79b and CD19 | CD79B, CD19 | Phase 1 | Non-hodgkin Lymphoma | Aug 2027 |
Diffuse Large B-Cell Lymphoma (7) Diffuse Large B-Cell Lymphoma (DLBCL) (4) Lymphoma, Non-Hodgkin (3) Diffuse Large B Cell Lymphoma (DLBCL) (3) DLBCL (2) Non-hodgkin Lymphoma (2) Lymphoma (2) Non-Hodgkin Lymphoma (1) Large B-Cell Lymphoma (1) B-cell Non-Hodgkin Lymphoma (1) Non-Hodgkins Lymphoma (1) Refractory Non-Hodgkin Lymphoma (1)
small molecule (2), mixed (2), antibody (1)
Johnson & Johnson (Janssen) (1) Memorial Sloan Kettering Cancer Center (1) Beijing Tongren Hospital (1) Roche (1) Marcela V. Maus, M.D.,Ph.D. (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.